LIAFENSINE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H22N4
Molecular Weight	366.4583
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C[C@@H](C2=CC3=C(C=CC=C3)C=C2)C4=CC=C(C=C4C1)C5=NN=C(N)C=C5

InChI

InChIKey=VCIBGDSRPUOBOG-QFIPXVFZSA-N

InChI=1S/C24H22N4/c1-28-14-20-13-19(23-10-11-24(25)27-26-23)8-9-21(20)22(15-28)18-7-6-16-4-2-3-5-17(16)12-18/h2-13,22H,14-15H2,1H3,(H2,25,27)/t22-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C24H22N4
Molecular Weight	366.4583
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24337079 | https://www.ncbi.nlm.nih.gov/pubmed/25961781 | https://www.denovobiopharma.com/index8.html

Liafensine is a potential first-in-class drug targeting treatment resistant depression (TRD). Single doses of liafensine have meaningful serotonin transporter and dopamine transporter occupancy and demonstrate an acceptable safety and tolerability profile in healthy control subjects. In a number of Phase 2 clinical trials conducted by Bristol-Myers Squibb in the treatment of TRD, liafensine showed high tolerance in TRD patients but it failed to demonstrate superiority to the continuation of an existing antidepressant in patients with treatment-resistant depression.

Originator

Approval Year

PubMed

Title	Date	PubMed
Comparison of different QT interval correction methods for heart rate and QT beat-to-beat method in a thorough QT study of triple monoamine reuptake inhibitor BMS-820836.	2015-10	25904041
Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies.	2015-08	25961781
Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836.	2015-02	25116481
Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study.	2014-06	24337079

Patents

Sample Use Guides

In Vivo Use Guide

Flexible (0.5-2 mg/d) or fixed dose of 1 mg/d or greater

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:04:38 GMT 2025` Edited by `admin` on `Mon Mar 31 21:04:38 GMT 2025`
Record UNII	R34ID086Z6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LIAFENSINE

Official Name

English

liafensine [INN]

Preferred Name

English

6-[(4S)-2-Methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine

Systematic Name

English

LIAFENSINE [USAN]

Common Name

English

Liafensine [WHO-DD]

Common Name

English

BMS-820836

Code

English

Code System Code Type Description

CAS

1198790-53-2